Literature DB >> 30632147

Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Francis J Herman1, Sherry Simkovic1, Giulio M Pasinetti1,2.   

Abstract

Dysfunctional immune activity is a physiological component of both Alzheimer's disease (AD) and major depressive disorder (MDD). The extent to which altered immune activity influences the development of their respective cognitive symptoms and neuropathologies remains under investigation. It is evident, however, that immune activity affects neuronal function and circuit integrity. In both disorders, alterations are present in similar immune networks and neuroendocrine signalling pathways, immune responses persist in overlapping neuroanatomical locations, and morphological and structural irregularities are noted in similar domains. Epidemiological studies have also linked the two disorders, and their genetic and environmental risk factors intersect along immune-activating pathways and can be synonymous with one another. While each of these disorders individually contains a large degree of heterogeneity, their shared immunological components may link distinct phenotypes within each disorder. This review will therefore highlight the shared immune pathways of AD and MDD, their overlapping neuroanatomical features, and previously applied, as well as novel, approaches to pharmacologically manipulate immune pathways, in each neurological condition. LINKED ARTICLES: This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2019        PMID: 30632147      PMCID: PMC6715609          DOI: 10.1111/bph.14569

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  317 in total

1.  Computational identification of gene-social environment interaction at the human IL6 locus.

Authors:  Steven W Cole; Jesusa M G Arevalo; Rie Takahashi; Erica K Sloan; Susan K Lutgendorf; Anil K Sood; John F Sheridan; Teresa E Seeman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

2.  Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.

Authors:  Paul Edison; Hilary A Archer; Alexander Gerhard; Rainer Hinz; Nicola Pavese; Federico E Turkheimer; Alexander Hammers; Yen Fong Tai; Nick Fox; Angus Kennedy; Martin Rossor; David J Brooks
Journal:  Neurobiol Dis       Date:  2008-08-15       Impact factor: 5.996

3.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Authors:  Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer
Journal:  Alzheimers Dement       Date:  2015-03-28       Impact factor: 21.566

4.  Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.

Authors:  Richard G Langley; Steven R Feldman; Chenglong Han; Brad Schenkel; Philippe Szapary; Ming-Chun Hsu; Jean-Paul Ortonne; Kenneth B Gordon; Alexa B Kimball
Journal:  J Am Acad Dermatol       Date:  2010-05-11       Impact factor: 11.527

5.  Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse.

Authors:  Patrick O McGowan; Aya Sasaki; Ana C D'Alessio; Sergiy Dymov; Benoit Labonté; Moshe Szyf; Gustavo Turecki; Michael J Meaney
Journal:  Nat Neurosci       Date:  2009-03       Impact factor: 24.884

6.  Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease.

Authors:  Michel Grothe; Helmut Heinsen; Stefan Teipel
Journal:  Neurobiol Aging       Date:  2012-11-15       Impact factor: 4.673

7.  Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1β in the aged hippocampus.

Authors:  G Aleph Prieto; Shikha Snigdha; David Baglietto-Vargas; Erica D Smith; Nicole C Berchtold; Liqi Tong; Dariush Ajami; Frank M LaFerla; Julius Rebek; Carl W Cotman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

8.  T-lymphocyte interleukin 6 receptor binding in patients with dementia of Alzheimer type.

Authors:  P Bongioanni; B Boccardi; M Borgna; B Rossi
Journal:  Arch Neurol       Date:  1998-10

9.  Plasma cortisol in Alzheimer's disease with or without depressive symptoms.

Authors:  Martina Zvěřová; Zdeněk Fišar; Roman Jirák; Eva Kitzlerová; Jana Hroudová; Jiří Raboch
Journal:  Med Sci Monit       Date:  2013-08-19

10.  Imbalance of Circulating Th17 and Regulatory T Cells in Alzheimer's Disease: A Case Control Study.

Authors:  Timo Jan Oberstein; Lava Taha; Philipp Spitzer; Janina Hellstern; Martin Herrmann; Johannes Kornhuber; Juan Manuel Maler
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

View more
  8 in total

1.  Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.

Authors:  Jin Yu; Hong Zhu; Saeid Taheri; William Mondy; Leonardo Bonilha; Gayenell S Magwood; Daniel Lackland; Robert J Adams; Mark S Kindy
Journal:  J Neurosci       Date:  2019-10-14       Impact factor: 6.167

Review 2.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

3.  Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine.

Authors:  J A Duce; X Zhu; L H Jacobson; P M Beart
Journal:  Br J Pharmacol       Date:  2019-09       Impact factor: 8.739

4.  Total Plasma Homocysteine and Depressive Symptoms in Older Hispanics.

Authors:  Fernando Castro; Jesús Melgarejo; Carlos A Chavez; Gabriel A de Erausquin; Joseph D Terwilliger; Joseph H Lee; Gladys E Maestre
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

5.  Linking late life depression and Alzheimer's disease: mechanisms and resilience.

Authors:  Sara L Weisenbach; Joseph Kim; Dustin Hammers; Kelly Konopacki; Vincent Koppelmans
Journal:  Curr Behav Neurosci Rep       Date:  2019-07-25

6.  Incidence and Risk Factors for Dementia in Type 2 Diabetes Mellitus: A Nationwide Population-Based Study in Korea.

Authors:  Ji Hee Yu; Kyungdo Han; Sanghyun Park; Hanna Cho; Da Young Lee; Jin Wook Kim; Ji A Seo; Sin Gon Kim; Sei Hyun Baik; Yong Gyu Park; Kyung Mook Choi; Seon Mee Kim; Nan Hee Kim
Journal:  Diabetes Metab J       Date:  2019-11-12       Impact factor: 5.376

7.  Creation of a gene expression portrait of depression and its application for identifying potential treatments.

Authors:  Stephen C Gammie
Journal:  Sci Rep       Date:  2021-02-15       Impact factor: 4.379

8.  Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis.

Authors:  Dezhi Yuan; Tian Kuan; Hu Ling; Hongkai Wang; Liping Feng; Qiuye Zhao; Jinfang Li; Jianhua Ran
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.